Ivermectin

Editor’s note: One of the studies cited in this story, conducted in Egypt, has since been retracted. The FDA has not approved ivermectin for use in treating or preventing COVID-19. Moreover, the Infectious Diseases Society of America recommends against ivermectin for the treatment of outpatients with COVID-19, unless in the context of a clinical trial.

Researchers from the University of Kentucky are conducting a clinical trial to evaluate the effectiveness of azithromycin, ivermectin and camostat mesylate alone or combined with hydroxychloroquine in high-risk patients with COVID-19.

A healthy 14-year-old male presents with a rash on the sole of his left foot. He first noticed that there was something there 1 to 2 weeks earlier and that it was pruritic. There have been no other associated complaints, disturbing symptoms or fever. His past medical history is unremarkable, and his family history reveals no sick contacts or anyone else with skin or foot problems. His travel history, however, reveals that he spent 7 days at a tropical beach resort with his family. They had returned home about 1 week before the foot lesion was first noted.